Identification of New Markers in the Hypereosinophilic Syndrome

Hypereosinophilic Syndrome Clinical Trial

— SHE  

Official title:

Identification of New Markers in the Hypereosinophilic Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01713504
• Other study ID #: 2008_29
• Secondary ID: 2009-A00314-53
• Status: Completed
• Phase: N/A
• Start date: June 29, 2010
• Est. completion date: July 2015

Study information

• Verified date: February 2019
• Source: University Hospital, Lille
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose is to characterize new hypereosinophilic syndrome biomarkers more informative and more accessible compared to those that we have already thanks to a proteomic approach. This will help the investigators to diagnose the this disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 41
• Est. completion date: July 2015
• Est. primary completion date: July 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• dated and signed informed consent

• virale serology negative or negative result less than 6 months

• virale serology negative for HBV or vaccinated patient

• insured

• virale serology negative or negative result less than 6 months

• negative pregnancy test or female menopause for at least 1 year

Exclusion Criteria:

• subject enable adult, under guardianship or under protective measures of justice

• Refusal or inability to give informed consent

• The hypereosinophilic syndrome explained origin other than than atopy, bullous pemphigoid, the Churg-Strauss syndrome and DRESS

Related Conditions & MeSH terms

• Hypereosinophilic Syndrome
• Syndrome

Intervention

Biological:
• biologie sample
comparison of biomarkers between HES, HE biomarkers data and control arms

Locations

Country	Name	City	State
France	CHRU, Hôpital Claude Huriez	Lille	Nord

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Lille

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The aim is to characterize, through an approach immunoprotéomique, new HES biomarkers more informative and easier access than those currently available to us. These biomarkers will help to the diagnosis of HES, compared with other causes of eosinophilia.		one month after patient inclusion